120 related articles for article (PubMed ID: 37995863)
1. Oncological characteristics of epidermal growth factor receptor-mutated clinical stage IA lung adenocarcinoma with radiologically pure-solid appearance.
Hattori A; Matsunaga T; Fukui M; Tomita H; Takamochi K; Suzuki K
J Thorac Cardiovasc Surg; 2023 Nov; ():. PubMed ID: 37995863
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of epidermal growth factor receptor-mutated stage I lung adenocarcinoma with radiologically solid features.
Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K
Eur J Cardiothorac Surg; 2022 Mar; 61(4):769-777. PubMed ID: 34791156
[TBL] [Abstract][Full Text] [Related]
3. Impact of a Ground-glass Opacity Component on c-Stage IA Lung Adenocarcinoma.
Li M; Xi J; Sui Q; Kuroda H; Hamanaka K; Bongiolatti S; Hong G; Zhan C; Feng M; Wang Q; Tan L
Semin Thorac Cardiovasc Surg; 2023 Winter; 35(4):783-795. PubMed ID: 35907612
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of a small component of ground-glass opacity in solid-dominant clinical stage IA non-small cell lung cancer.
Watanabe Y; Hattori A; Nojiri S; Matsunaga T; Takamochi K; Oh S; Suzuki K
J Thorac Cardiovasc Surg; 2022 Mar; 163(3):791-801.e4. PubMed ID: 33516459
[TBL] [Abstract][Full Text] [Related]
5. Distinct Clinicopathologic Characteristics and Prognosis Based on the Presence of Ground Glass Opacity Component in Clinical Stage IA Lung Adenocarcinoma.
Hattori A; Hirayama S; Matsunaga T; Hayashi T; Takamochi K; Oh S; Suzuki K
J Thorac Oncol; 2019 Feb; 14(2):265-275. PubMed ID: 30368010
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of a ground-glass opacity component in clinical stage IA non-small cell lung cancer.
Hattori A; Suzuki K; Takamochi K; Wakabayashi M; Aokage K; Saji H; Watanabe SI;
J Thorac Cardiovasc Surg; 2021 Apr; 161(4):1469-1480. PubMed ID: 32451073
[TBL] [Abstract][Full Text] [Related]
7. The prognostic impact of the ground-glass opacity component in nearly pure-solid stage IA non-small-cell lung cancer.
Kamigaichi A; Tsutani Y; Mimae T; Miyata Y; Shimada Y; Ito H; Nakayama H; Ikeda N; Okada M
Eur J Cardiothorac Surg; 2022 Aug; 62(3):. PubMed ID: 35293580
[TBL] [Abstract][Full Text] [Related]
8. Pan-Driver-Negatives versus Epidermal Growth Factor Receptor Mutants for C-Stage IA Lung Adenocarcinoma with Ground-Glass Opacity.
Li M; Xi J; Zhang H; Jin X; Zhang J; Feng M; Zhan C; Wang Q
Ann Thorac Cardiovasc Surg; 2022 Oct; 28(5):320-328. PubMed ID: 35644565
[TBL] [Abstract][Full Text] [Related]
9. Prognostic influence of a ground-glass opacity component in hypermetabolic lung adenocarcinoma.
Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K
Eur J Cardiothorac Surg; 2022 Jan; 61(2):249-256. PubMed ID: 34632486
[TBL] [Abstract][Full Text] [Related]
10. Ground glass opacity resection extent assessment trial
Li H; Wang Y; Chen Y; Zhong C; Fang W
Front Oncol; 2023; 13():1052796. PubMed ID: 36741022
[TBL] [Abstract][Full Text] [Related]
11. A clinicopathological study of lung adenocarcinomas with pure ground-glass opacity > 3 cm on high-resolution computed tomography.
Sun K; Xie H; Zhao J; Wang B; Bao X; Zhou F; Zhang L; Li W
Eur Radiol; 2022 Jan; 32(1):174-183. PubMed ID: 34132876
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of CT-defined ground-glass opacity in early-stage lung adenocarcinomas: a single-center study and meta-analysis.
Lee JH; Choi Y; Hong H; Kim YT; Goo JM; Kim H
Eur Radiol; 2024 Mar; 34(3):1905-1920. PubMed ID: 37650971
[TBL] [Abstract][Full Text] [Related]
13. Importance of Ground Glass Opacity Component in Clinical Stage IA Radiologic Invasive Lung Cancer.
Hattori A; Matsunaga T; Takamochi K; Oh S; Suzuki K
Ann Thorac Surg; 2017 Jul; 104(1):313-320. PubMed ID: 28433219
[TBL] [Abstract][Full Text] [Related]
14. Indications for sublobar resection of clinical stage IA radiologic pure-solid lung adenocarcinoma.
Hattori A; Matsunaga T; Takamochi K; Oh S; Suzuki K
J Thorac Cardiovasc Surg; 2017 Sep; 154(3):1100-1108. PubMed ID: 28629842
[TBL] [Abstract][Full Text] [Related]
15. Role of ground-glass opacity in pure invasive and lepidic component in pure solid lung adenocarcinoma for predicting aggressiveness.
Mimae T; Miyata Y; Tsutani Y; Shimada Y; Ito H; Nakayama H; Ikeda N; Okada M
JTCVS Open; 2022 Sep; 11():300-316. PubMed ID: 36172403
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and prognosis of clinical N0 non-small cell lung cancer exceeding 30 mm.
Kagimoto A; Tsutani Y; Handa Y; Mimae T; Miyata Y; Okada M
Jpn J Clin Oncol; 2020 Oct; 50(11):1306-1312. PubMed ID: 32901276
[TBL] [Abstract][Full Text] [Related]
17. Oncologic outcomes of segmentectomy for stage IA radiological solid-predominant lung cancer >2 cm in maximum tumour size.
Hattori A; Matsunaga T; Fukui M; Takamochi K; Oh S; Suzuki K
Interact Cardiovasc Thorac Surg; 2022 Nov; 35(6):. PubMed ID: 36161317
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Impact of the Findings on Thin-Section Computed Tomography in Patients with Subcentimeter Non-Small Cell Lung Cancer.
Hattori A; Matsunaga T; Hayashi T; Takamochi K; Oh S; Suzuki K
J Thorac Oncol; 2017 Jun; 12(6):954-962. PubMed ID: 28257958
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of a ground glass opacity component in the clinical T classification of non-small cell lung cancer.
Hattori A; Matsunaga T; Takamochi K; Oh S; Suzuki K
J Thorac Cardiovasc Surg; 2017 Dec; 154(6):2102-2110.e1. PubMed ID: 28947198
[TBL] [Abstract][Full Text] [Related]
20. Solitary ground-glass opacity nodules of stage IA pulmonary adenocarcinoma: combination of 18F-FDG PET/CT and high-resolution computed tomography features to predict invasive adenocarcinoma.
Zhou J; Li Y; Zhang Y; Liu G; Tan H; Hu Y; Xiao J; Shi H
Oncotarget; 2017 Apr; 8(14):23312-23321. PubMed ID: 28423576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
